As of June 23, 2025, Egetis Therapeutics AB (publ) (EGTX.ST) reports a Gross Margin of 74.84%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Egetis Therapeutics AB (publ)'s Gross Margin
Over recent years, Egetis Therapeutics AB (publ)'s Gross Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2024-12-31 | 74.84% |
| 2023-12-31 | 80.90% |
| 2022-12-31 | 72.12% |
| 2021-12-31 | 79.46% |
| 2020-12-31 | 95.34% |
This gradual decrease highlights how Egetis Therapeutics AB (publ) manages its operational efficiency and pricing power over time.
Comparing Egetis Therapeutics AB (publ)'s Gross Margin to Peers
To better understand Egetis Therapeutics AB (publ)'s position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Egetis Therapeutics AB (publ) (EGTX.ST) | 74.84% |
| Sensorion SA (ALSEN.PA) | 7775.20% |
| Targovax ASA (TRVX.OL) | 7775.20% |
| Geneuro SA (GNRO.PA) | 7775.20% |
| E-Therapeutics PLC (ETX.L) | 100.00% |
| ReNeuron Group PLC (RENE.L) | 100.00% |
Compared to its competitors, Egetis Therapeutics AB (publ)'s Gross Margin is about average compared to peers, indicating industry-standard operational efficiency.